Currently, the development of low-reflection electromagnetic interference (EMI) shielding composite materials for mitigating secondary electromagnetic wave pollution has become a major research focus. However, achieving thinness, high toughness, low reflectivity, and multifunctionality in flexible EMI shielding films remains a challenge. To address this issue, Benliang Liang and Luting Yan from Beijing Jiaotong University, in collaboration with Lan Zhang from Luoyang Institute of Science and Technology, have introduced a "magnetic-electric" Janus structure EMI shielding composite film composed of MXene nanosheets, carbonized ZIF67 (CZIF67) nanoparticles and aramid nanofibers (ANF), balancing thinness(80 μm), high-strength-toughness composite film (110±7 MPa tensile strength, 21% strain, 14.91±0.9 MJ·m⁻³ toughness), (4.3–4.5 dB in 8.2–9.6 GHz) with 44.8 dB SET in the X-band. In addition, This multifunctional material simultaneously integrates electrothermal/photothermal conversion, fire-alarm response, and infrared stealth capabilities, demonstrating exceptional potential for next-generation wearable electronics and harsh-environment applications.

Ulcerative colitis (UC), a prevalent chronic inflammatory bowel disease, faces limitations in current treatments due to poor efficacy and side effects. Emodin (EMO), a natural anti-inflammatory compound, shows promise but is hindered by low solubility and bioavailability. A research team led by Prof. Xueye Chen from Ludong University developed a novel micromixer combined with machine learning to enable one-step synthesis of targeted emodin liposomes (Apt-EMO@Lip), significantly enhancing therapeutic efficiency and paving new avenues for UC treatment.

As part of an effort to better evaluate how pre-weaned calf and stocker calf treatments influence feedlot performance, Daniel Rivera, associate professor of animal science with the University of Arkansas System Division of Agriculture and Paul Beck, a professor and extension specialist for beef nutrition with Oklahoma State University’s department of animal and food sciences, published a summary of research on the topic in a special issue of Applied Animal Sciences, the American Registry of Professional Animal Scientists' official journal.

Pelvic organ prolapse (POP), a condition whose development is shaped by both genetic and clinical risk factors, significantly impairs women’s quality of life, yet genetic insights into non-European populations and comprehensive risk models that integrate genetic and clinical data remain insufficiently explored. To address this gap, the first polygenic risk score (PRS) for POP in the Chinese population was constructed, leveraging 20 disease-associated genetic variants derived from the largest available genome-wide association study (GWAS) on POP. The research analyzed two cohorts: a discovery cohort comprising 576 POP cases and 623 controls, and a validation cohort with 264 cases and 200 controls. Results confirmed that the POP case group had a significantly higher PRS than the control group; notably, women in the top 10% of PRS values (highest genetic risk) had an odds ratio of 2.6 for developing POP compared to those in the bottom 10% (lowest genetic risk). A high PRS was also found to correlate significantly with POP occurrence in specific subgroups: women over 50 years old and those with one or no childbirths. Additionally, an integrated prediction model combining PRS with clinical risk factors demonstrated better predictive accuracy than existing PRS-only models. This combined risk assessment tool proves robust for POP risk prediction and stratification, providing valuable guidance for personalized preventive measures and treatment strategies in future clinical practice.

Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB homolog 5 (ALKBH5)—an N⁶-methyladenosine (m⁶A) demethylase with known roles in regulating angiogenesis in cardiovascular and eye diseases—has emerged as a key player in this process. In imiquimod (IMQ)-induced psoriasis mouse models, ALKBH5 was found to be upregulated in skin lesions compared to control groups, with co-localization with cluster of differentiation 31 (CD31), an endothelial cell marker linked to angiogenesis. ALKBH5-deficient (ALKBH5-KO) mice showed reduced IMQ-induced psoriatic dermatitis, with histological improvements including thinner epidermis, less hyperkeratosis, fewer dermal capillaries, and decreased inflammatory cell infiltration. These mice also exhibited alleviated angiogenesis in psoriatic lesions, mediated by downregulation of the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway. In vitro, human umbilical vein endothelial cells (HUVECs) treated with IL-17A— a cytokine critical to psoriasis pathogenesis—showed significant upregulation of ALKBH5, which further promoted the expression of angiogenesis-related cytokines and endothelial cell proliferation. ALKBH5 knockdown in HUVECs suppressed cell proliferation and angiogenesis, while overexpression had the opposite effect, with both processes regulated via the AKT-mTOR pathway. Collectively, these findings highlight ALKBH5’s pivotal role in psoriatic dermatitis and angiogenesis, identifying it as a potential therapeutic target for psoriasis.